Cyclacel Pharmaceuticals (CYCC) Receives Media Sentiment Rating of 0.08
Media headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.8776503019124 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
NASDAQ:CYCC traded up $0.10 on Friday, reaching $1.53. 116,043 shares of the stock traded hands, compared to its average volume of 70,419. Cyclacel Pharmaceuticals has a 1-year low of $1.28 and a 1-year high of $2.27.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). sell-side analysts expect that Cyclacel Pharmaceuticals will post -0.53 EPS for the current year.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Recommended Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.